Lockheed Martin jumps into bionic suit market; Greatbatch shows off spinal cord stimulation device

 @FierceMedDev: FDA sticks Class I tag on Symbios' pump recall. Story | Follow @FierceMedDev

 @MarkHFierce: China's Dehaier Medical Systems will be one to watch in 2013 as it pursues govt. healthcare contracts at home. Story | Follow @MarkHFierce

 @DamianFierce: Third Rock Ventures-backed DC Devices hauled in another $10+ million for its heart failure device. More | Follow @DamianFierce

> NuVasive hit with FDA warning letter over spine device. More

> Johns Hopkins team takes step toward creating migraine blood Dx. Story

> Venture-backed Invuity has launched its minimally invasive visualization device, the Eigr Saber Waveguide. More

> Lockheed Martin ($LMT) is jumping into the market for bionic suits, competing in a field analysts say could be worth $400 million by 2020. Article

> Greatbatch ($GB) debuted its new spinal cord stimulation system for investors this week in New York. It's designed to treat pain. Story

> Researchers developing new medical technologies are looking to mimic nature in design and function. Story

> A Johnson & Johnson ($JNJ) sales rep indicted for reselling medical devices obtained from hospitals to which she previously sold the same products is spurring a U.S. Supreme Court case over whether the assets of a defendant can be frozen before trial. Item

> Implanting an endovascular stent into the sinus can help treat tinnitus and visual function, according to a study. Report

> Biomet is teaming up with OrthoSensor to co-promote the former's Vanguard Complete Knee System and the latter's Verasense, which can provide real-time knee kinetic data to surgeons. Release

Biotech News

 @FierceBiotech: FDA staff review raises big questions about fate of Titan's Probuphine. More | Follow @FierceBiotech

 @JohnCFierce: Biopharma's Top R&D Spenders - 2012. Special Report | Follow @JohnCFierce

 @RyanMFierce: Fierce's top 5 feats in life sciences 'gamification'. Special Report | Follow @RyanMFierce

> FDA staff review raises big questions about fate of Titan's Probuphine. More

> One foot in biotech graveyard, NeuroSearch is calling it quits. Article

> NPS Pharma goes global with $80M deal to buy back Gattex rights. Story

Pharma News

 @FiercePharma: Have generics reached a saturation point? With 84% utilization, maybe. And specialty prices are soaring. Article | Follow @FiercePharma

 @EricPFierce: 600,000 bottles of Glenmark's generic Singulair recalled for fishy smell. Recalls for odors not a rarity. Article | Follow @EricPFierce

> Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy. News

> Senator questions Pfizer's $2,000-a-month price on Xeljanz. Report

> Big Pharma drools after $25B market for pricey pet care. More

Biotech Research News

 @EmilyMFierce: Not to alarm anyone, but new research suggests that the black plague may still be a threat today. Post | Follow @EmilyMFierce

> Protein points to hormone therapy-resistant prostate cancer. Report

> Stem cell treatment could accelerate diabetic wound healing. Story

> Mount Sinai gets $5M from NIH to study neurological voice condition. Item

> Scripps, Takeda renew pact to find CNS treatments. More

Pharma Manufacturing News

> Claris a buyout candidate as shortages remake injectables biz. Item

> AmerisourceBergen gets Walgreen, Boots biz. Story

> FDA now inspecting 'high risk' compounders. News

> Lilly warehouse thieves followed risk-assessment 'road map.' Report